Landmark Ideas Series: Dr. W. Ian Lipkin

Speaker: W. Ian Lipkin, MD, at Columbia University

Date: October 5, 2023 at 4:00PM - 5:30PM

Talk details will be forthcoming.

Lipkin is the Director for the Center of Infection and Immunity with the Mailman School of Public Health at Columbia University, the John Snow Professor of Epidemiology at the Columbia University Vagelos College of Physicians and Surgeons, Director for the Global Alliance for Preventing Pandemics (GAPP), and Director of the Center for Solutions for ME/CFS.

He is internationally recognized for his contributions to global public health by being at the forefront of outbreak response and through the innovative methods he developed for infectious diseases diagnosis, surveillance, and discovery. These advances have been critical in replacing culture-dependent methods of global health management by creating new criteria for disease causation and de-linking spurious associations between putative agents and diseases. Such examples include refuting the MMR vaccine having a role in autism and XMRV in ME/CFS.

Some of his most prestigious honors include Pew Scholar, Walter Reed Distinguished Lecturer, the Drexel Prize in Translational Medicine, the Mendel Medal, the International Science and Technology Cooperation Award of the Peoples Republic of China, and recipient of an award of appreciation given by the Chinese government in the 70thanniversary of the People’s Republic of China for his service to the country during the SARS epidemic along with the subsequent scientific support he has given since.

Lipkin consulted on testing and site safety protocols for the 2020 Democratic National Convention and the 2021 Academy Awards. He promotes public health awareness via print and broadcast media and served as scientific advisor to the 2011 Soderbergh film “Contagion”.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.